Related references
Note: Only part of the references are listed.Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
Hajime Nagasu et al.
DIABETES CARE (2021)
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Hiddo J. L. Heerspink et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
Wajd Alkabbani et al.
BMJ OPEN DIABETES RESEARCH & CARE (2021)
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
Meir Schechter et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Trends in Diabetes Treatment and Control in US Adults, 1999-2018
Michael Fang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Uptake of new antidiabetic medicines in 11 European countries
Nika Mardetko et al.
BMC ENDOCRINE DISORDERS (2021)
Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: A retrospective cohort study
Andrea O. Y. Luk et al.
PLOS MEDICINE (2020)
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
Vikas S. Sridhar et al.
DIABETES OBESITY & METABOLISM (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis
Avivit Cahn et al.
DIABETES OBESITY & METABOLISM (2019)
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
A. J. Scheen
DIABETES & METABOLISM (2019)
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEA® trial
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Hiddo J L Heerspink et al.
Lancet Diabetes & Endocrinology (2019)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores
Samy Suissa et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
A Clinical Practice Guideline to Guide a System Approach to Diabetes Care in Hong Kong
Ip Tim Lau
DIABETES & METABOLISM JOURNAL (2017)
An update on DPP-4 inhibitors in the management of type 2 diabetes
Avivit Cahn et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
The new Asian modified CKD-EPI equation leads to more accurate GFR estimation in Chinese patients with CKD
Jinghua Wang et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Katherine R. Tuttle et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
Josef Coresh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs
T. Stuermer et al.
JOURNAL OF INTERNAL MEDICINE (2014)
A comparison of 12 algorithms for matching on the propensity score
Peter C. Austin
STATISTICS IN MEDICINE (2014)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Predictors of Estimated GFR Decline in Patients with Type 2 Diabetes and Preserved Kidney Function
Giacomo Zoppini et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Metformin and the Risk of Cancer Time-related biases in observational studies
Samy Suissa et al.
DIABETES CARE (2012)
Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes
Peter C. Austin
JOURNAL OF CLINICAL EPIDEMIOLOGY (2010)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Share Paper
